SG11201710695XA - 1,4-disubstituted imidazole derivative - Google Patents

1,4-disubstituted imidazole derivative

Info

Publication number
SG11201710695XA
SG11201710695XA SG11201710695XA SG11201710695XA SG11201710695XA SG 11201710695X A SG11201710695X A SG 11201710695XA SG 11201710695X A SG11201710695X A SG 11201710695XA SG 11201710695X A SG11201710695X A SG 11201710695XA SG 11201710695X A SG11201710695X A SG 11201710695XA
Authority
SG
Singapore
Prior art keywords
imidazole derivative
disubstituted imidazole
disubstituted
derivative
imidazole
Prior art date
Application number
SG11201710695XA
Other languages
English (en)
Inventor
Hitoshi Ban
Manabu Kusagi
Shingo Tojo
Futoshi Hasegawa
Miki Hashizume
Original Assignee
Sumitomo Dainippon Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Dainippon Pharma Co Ltd filed Critical Sumitomo Dainippon Pharma Co Ltd
Publication of SG11201710695XA publication Critical patent/SG11201710695XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00Carboxylic acid amides
    • C07C233/88Carboxylic acid amides having nitrogen atoms of carboxamide groups bound to an acyclic carbon atom and to a carbon atom of a six-membered aromatic ring wherein at least one ortho-hydrogen atom has been replaced
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SG11201710695XA 2015-06-22 2016-06-21 1,4-disubstituted imidazole derivative SG11201710695XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2015125174 2015-06-22
JP2015244856 2015-12-16
PCT/JP2016/068423 WO2016208591A1 (ja) 2015-06-22 2016-06-21 1,4-ジ置換イミダゾール誘導体

Publications (1)

Publication Number Publication Date
SG11201710695XA true SG11201710695XA (en) 2018-01-30

Family

ID=57584875

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201710695XA SG11201710695XA (en) 2015-06-22 2016-06-21 1,4-disubstituted imidazole derivative

Country Status (13)

Country Link
US (3) US10807945B2 (zh)
EP (1) EP3312170A4 (zh)
JP (1) JP6692354B2 (zh)
KR (1) KR20180028456A (zh)
CN (1) CN107922386B (zh)
AU (1) AU2016284398C1 (zh)
CA (1) CA2990583A1 (zh)
HK (1) HK1248226A1 (zh)
PH (1) PH12017502388A1 (zh)
RU (1) RU2741000C2 (zh)
SG (1) SG11201710695XA (zh)
TW (1) TW201713642A (zh)
WO (1) WO2016208591A1 (zh)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016208591A1 (ja) * 2015-06-22 2016-12-29 大日本住友製薬株式会社 1,4-ジ置換イミダゾール誘導体
JPWO2016208592A1 (ja) 2015-06-22 2018-04-05 大日本住友製薬株式会社 二環性複素環アミド誘導体
US10898469B2 (en) 2016-02-26 2021-01-26 Sumitomo Dainippon Pharma Co., Ltd. Imidazolylamide derivative
US20200268728A1 (en) * 2016-12-20 2020-08-27 Sumitomo Dainippon Pharma Co., Ltd. Drug targeting cancer stem cell
JP6775483B2 (ja) * 2016-12-20 2020-10-28 大日本住友製薬株式会社 1,4−ジ置換イミダゾール誘導体からなる医薬
JP7123809B2 (ja) * 2016-12-20 2022-08-23 住友ファーマ株式会社 未分化iPS細胞の除去剤
CA3092255A1 (en) * 2018-03-20 2019-09-26 Sumitomo Dainippon Pharma Co., Ltd. Dihydrochromene derivatives
US10829485B2 (en) * 2018-04-06 2020-11-10 Black Belt Tx Ltd ATF6 inhibitors and uses thereof
JP7287929B2 (ja) * 2019-09-25 2023-06-06 住友ファーマ株式会社 ジヒドロクロメン誘導体を含有する医薬

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5359664A (en) * 1976-11-10 1978-05-29 Sumitomo Chem Co Ltd Novel imidazole derivatives
US4140788A (en) * 1976-11-10 1979-02-20 Sumitomo Chemical Company, Limited N-Substituted imidazolecarboxamide derivatives
JPH11513382A (ja) * 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング 5員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
WO1999003858A1 (fr) 1997-07-15 1999-01-28 Japan Energy Corporation Derives purine et leur application medicinale
GEP20084420B (en) 2004-03-23 2008-07-10 Pfizer Prod Inc Use of imidazole compounds for the treatment of neurodegenerative disorders
SE0401653D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab New compounds
EP1874734A1 (en) 2005-02-16 2008-01-09 Solvay Pharmaceuticals B.V. 1h-imidiazole derivatives as cannabinoid cb2 receptor modulators
AR052666A1 (es) * 2005-02-16 2007-03-28 Solvay Pharm Bv Derivados de 1h-imidazol como moduladores del receptor cannabinoide cb2
DE102005008183A1 (de) 2005-02-23 2006-08-31 Bayer Healthcare Ag Heterocyclylamid-substituierte Imidazole
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds
AU2006327316A1 (en) 2005-12-23 2007-06-28 Astrazeneca Ab Imidazoles as GABA-B receptor modulators
WO2008073461A2 (en) 2006-12-11 2008-06-19 Wyeth Ion channel modulators
GB0722075D0 (en) * 2007-11-09 2007-12-19 Smithkline Beecham Corp Compounds
PL2688885T3 (pl) * 2011-03-22 2016-12-30 Amidy kwasu N-(1,3,4-oksdiazol-2-ilo)arylokarboksylowego i ich zastosowanie jako herbicydów
PL2772484T3 (pl) * 2011-10-18 2017-10-31 Astellas Pharma Inc Bicykliczny związek heterocykliczny
EP3127907A4 (en) * 2014-03-31 2018-04-04 Boston Biomedical, Inc. New tricyclic quinone derivative
GB201416754D0 (en) * 2014-09-23 2014-11-05 Mission Therapeutics Ltd Novel compounds
WO2016208591A1 (ja) 2015-06-22 2016-12-29 大日本住友製薬株式会社 1,4-ジ置換イミダゾール誘導体

Also Published As

Publication number Publication date
US20170166552A1 (en) 2017-06-15
EP3312170A4 (en) 2018-12-12
AU2016284398C1 (en) 2021-01-07
US10807945B2 (en) 2020-10-20
RU2741000C2 (ru) 2021-01-22
PH12017502388A1 (en) 2018-07-09
CN107922386A (zh) 2018-04-17
US9828362B2 (en) 2017-11-28
US11661397B2 (en) 2023-05-30
WO2016208591A1 (ja) 2016-12-29
KR20180028456A (ko) 2018-03-16
JP6692354B2 (ja) 2020-05-13
CN107922386B (zh) 2021-04-02
TW201713642A (zh) 2017-04-16
EP3312170A1 (en) 2018-04-25
CA2990583A1 (en) 2016-12-29
US20210171440A1 (en) 2021-06-10
AU2016284398A1 (en) 2018-02-01
RU2018102087A (ru) 2019-07-23
JPWO2016208591A1 (ja) 2018-04-05
AU2016284398B2 (en) 2020-08-06
US20180230085A1 (en) 2018-08-16
HK1248226A1 (zh) 2018-10-12
RU2018102087A3 (zh) 2019-12-25

Similar Documents

Publication Publication Date Title
IL288232A (en) 1,7- naphthyridine as immunomodulators
IL264092A (en) 1, 3-dihydroxy-phenyl derivatives are useful as immunomodulators
ZA201707424B (en) Novel 5-substituted imidazole derivatives
HK1253048A1 (zh) 1,4-取代的哌啶衍生物
ZA201605622B (en) 1,3-benzodioxole derivative
ZA201700019B (en) Substituted [1,2,4]triazole compounds
ZA201802451B (en) 2,4-dihydroxy-nicotinamides as apj agonists
IL247276A0 (en) [1,2,4]-converted triazole and imidazole compounds as fungicides
SG11201710695XA (en) 1,4-disubstituted imidazole derivative
IL247319B (en) History of 2-hydroxy-6,4-diphenyl-[5,3,1]triazine as mpges-1 inhibitors
IL249299A0 (en) Modified [4,2,1]triazole and imidazole compounds as fungicides
IL247728B (en) Piperdines -(3,5 di-converted-pyridine-4-yl)-1
EP3386952A4 (en) SUBSTITUTED BENZIMIDAZOLIUM, PYRIDO-IMIDAZOLIUM OR PYRAZINO-IMIDAZOLIUM COMPOUNDS AS CHEMOTHERAPEUTICS
ZA201807129B (en) Griseofulvin compound
IL248793A0 (en) Triazole and [4,2,1]imidazole compounds are converted as fungicides
HK1245269A1 (zh) 咪唑衍生物
SG11201702009WA (en) Antimicrobial imidazolium compounds
SG11201803584RA (en) 1,4-dicarbonyl-piperidyl derivatives
HK1254800A1 (zh) 2,3,4,5-四氫吡啶-6-胺衍生物
ZA201805791B (en) 5-methyl-6-phenyl-4,5-dihydro-2h-pyridazin-3-one derivative
HK1259107A1 (zh) 氨基唑衍生物
EP3444345C0 (en) MICRORNA-143 DERIVATIVE
GB201519732D0 (en) Mrbr.2
GB201421251D0 (en) Fuckface unstoppable live, volume 1
GB201421252D0 (en) Fuckface unstoppable live, volume 2